Daiichi Sankyo Co., Ltd.





Delayed Japan Exchange 05:45:00 18/07/2024 BST 5-day change 1st Jan Change
5,998 JPY -1.23% Intraday chart for Daiichi Sankyo Co., Ltd. -0.48% +54.91%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Daiichi Sankyo's Disposes Shares as Restricted Compensation MT
Daiichi Sankyo Opens New Affiliate for Oncology in Greece CI
Financials lift Japanese shares on rate-hike speculation RE
Daiichi Sankyo Buys Back 13.5 Billion Yen Worth of Shares in June MT
Sanofi eyes German insulin investment of up to $1.6 bln, source says RE
Daiichi Sankyo Buys Back Shares MT
Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2024. CI
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug RE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer CI
Health Care Down as Moderna Slides -- Health Care Roundup DJ
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients MT
Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration MT
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May MT
Transcript : Daiichi Sankyo Company, Limited - Special Call
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38% MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population CI
RevolKa Signs Master Service Agreement with Daiichi Sankyo CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial MT
Chart Daiichi Sankyo Co., Ltd.
More charts
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
6,073 JPY
Average target price
6,306 JPY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.
  5. Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration